Alaunos Therapeutics(TCRT) - 2024 Q3 - Quarterly Results

Item 1.02 Termination of a Material Definitive Agreement Alaunos Therapeutics terminated its Sleeping Beauty platform license with Precigen due to patent expiration, exploring strategic options - Alaunos provided written notice to Precigen on October 4, 2024, to terminate the Amended and Restated License Agreement for Sleeping Beauty-transposed neoantigen T-cell receptors[3] - The termination was a strategic decision, partly due to the non-viral Sleeping Beauty gene transfer platform patent expiring in 2026[4] - The company is actively exploring various strategic alternatives, including acquisition, merger, asset sale, or partnerships[4] Item 2.02 Results of Operations and Financial Condition Alaunos shifts focus to an internally developed small molecule oral obesity program, extending cash runway into Q1 2025 via overhead reductions - The company is advancing an internally developed small molecule oral obesity program, aiming for a differentiated non-hormonal profile[5] - Reductions in overhead expenditures have successfully extended the company's cash runway into Q1 2025[5] Obesity Program Development Milestones | Milestone | Target Date | | :--------------------------------------------- | :---------- | | Initiate in vitro testing of candidates | Q4 2024 | | Conduct in vivo efficacy study | H1 2025 | | Initiate nonclinical and IND-enabling activities | 2025 | - Successful execution of the obesity program's development plan depends on future study results and ability to raise additional capital or partner assets[5] Forward-Looking Statements This section cautions investors that the report contains forward-looking statements subject to significant risks and uncertainties, urging against undue reliance - The report includes forward-looking statements regarding strategic reprioritization, capital raising, and consummation of strategic transactions like mergers or partnerships[9] - Statements regarding future expenses, cash needs, intellectual property, and progress of the small molecule oral obesity program are also forward-looking[9] - These statements involve known and unknown risks, with the company assuming no obligation to update them, urging investors not to place undue reliance[8][9] Item 9.01 Financial Statements and Exhibits This section lists exhibits filed with the Form 8-K, specifically Exhibit 104, the Interactive Data File within the Inline XBRL document - The report includes Exhibit 104, an Interactive Data File embedded within the Inline XBRL document[7]